Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?
- 1 June 2017
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (16) , 1858-1859
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN TrialJournal of Clinical Oncology, 2017
- Cabozantinib versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinomaBritish Journal of Cancer, 2015
- First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDCBritish Journal of Cancer, 2014
- Flare-up: An often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitorsActa Oncologica, 2009